At the same time, DHG’s business lines are adjusted and added from January 01 2018 such as manufacture of drugs; real estate activities with own or leased property; wholesale of other household products…
Previously, at the General Meeting 2017, DHG approved to increase the FOL to 49 per cent. However, in order to gain the maximum benefits from attracting foreign capital and increase the liquidity of DHG's shares, DHG will lift the FOL to 100 per cent from early 2018.
This is a good chance for foreign investors who desire to acquire stakes of this leading domestic pharmaceutical company in Vietnam.
DHG now has Tokyo-based Taisho Pharmaceutical Co., Ltd as a foreign shareholder with 24.5 per cent and The State Capital Investment Corporation as the main local shareholder with 43 per cent.
According to DHG’s income statement, in the first 6 months of 2017, DHG earned a net revenue of VND1,808 billion (equivalent to US$79 million) and after-tax profit of VND359 billion (roughly US$15.7 million). The average earning per share in the first six months reached VND2,470 (appropriately US$0.11), a year-on-year rise of 6.9 per cent.
According to the plan in 2017, DHG strives for the revenue of VND4,369 billion (roughly US192 million), pre-tax profit of VND820 billion (equivalent to US$3.6 million) and cash dividend of 30 per cent.
